Molecular pathogenesis of craniopharyngioma: Switching from a surgical approach to a biological one

Benedetta Ludovica Pettorini, Paolo Frassanito, Massimo Caldarelli, Gianpiero T. Tamburrini, Luca Massimi, Concezio Di Rocco

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Craniopharyngioma has long been considered a benign tumor because of its pathological aspect. This primordial view of craniopharyngioma fit with the primitive treatment attempts based on blind resection of the tumor each time it recurred. The limits of this management strategy were proven early by the high morbidity related to the resection and recurrence risk despite radical lesion removal. Nowadays, craniopharyngioma must be considered a complex molecular disease, and a detailed explanation of the mechanisms underlying its aggressive biological and clinical behavior, despite some benign pathological features, would be the first step toward defining the best management of craniopharyngioma. Indeed, advances in the knowledge of the molecular mechanisms at the base of craniopharyngioma oncogenesis will lead to comprehension of the critical checkpoints involved in neoplastic transformation. The final research target will be the definition of new biological agents able to reverse the neoplastic process by acting on these critical checkpoints. This biological approach will lead to a refined therapy combining higher efficacy and safety with lower morbidity. In this paper the authors reveal state-of-the-art comprehension of the molecular biology of craniopharyngioma and the consequent therapeutic implications.

Original languageEnglish
JournalNeurosurgical Focus
Volume28
Issue number4
DOIs
Publication statusPublished - Apr 2010

Fingerprint

Craniopharyngioma
Morbidity
Neoplastic Processes
Biological Factors
Molecular Biology
Neoplasms
Carcinogenesis
Safety
Recurrence
Therapeutics
Research

Keywords

  • Craniopharyngioma
  • Molecular biology
  • Oncogenetic mechanism

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Pettorini, B. L., Frassanito, P., Caldarelli, M., Tamburrini, G. T., Massimi, L., & Di Rocco, C. (2010). Molecular pathogenesis of craniopharyngioma: Switching from a surgical approach to a biological one. Neurosurgical Focus, 28(4). https://doi.org/10.3171/2010.1.FOCUS09300

Molecular pathogenesis of craniopharyngioma : Switching from a surgical approach to a biological one. / Pettorini, Benedetta Ludovica; Frassanito, Paolo; Caldarelli, Massimo; Tamburrini, Gianpiero T.; Massimi, Luca; Di Rocco, Concezio.

In: Neurosurgical Focus, Vol. 28, No. 4, 04.2010.

Research output: Contribution to journalArticle

Pettorini, BL, Frassanito, P, Caldarelli, M, Tamburrini, GT, Massimi, L & Di Rocco, C 2010, 'Molecular pathogenesis of craniopharyngioma: Switching from a surgical approach to a biological one', Neurosurgical Focus, vol. 28, no. 4. https://doi.org/10.3171/2010.1.FOCUS09300
Pettorini, Benedetta Ludovica ; Frassanito, Paolo ; Caldarelli, Massimo ; Tamburrini, Gianpiero T. ; Massimi, Luca ; Di Rocco, Concezio. / Molecular pathogenesis of craniopharyngioma : Switching from a surgical approach to a biological one. In: Neurosurgical Focus. 2010 ; Vol. 28, No. 4.
@article{eb9cd48d270045b395292e0f1afa8714,
title = "Molecular pathogenesis of craniopharyngioma: Switching from a surgical approach to a biological one",
abstract = "Craniopharyngioma has long been considered a benign tumor because of its pathological aspect. This primordial view of craniopharyngioma fit with the primitive treatment attempts based on blind resection of the tumor each time it recurred. The limits of this management strategy were proven early by the high morbidity related to the resection and recurrence risk despite radical lesion removal. Nowadays, craniopharyngioma must be considered a complex molecular disease, and a detailed explanation of the mechanisms underlying its aggressive biological and clinical behavior, despite some benign pathological features, would be the first step toward defining the best management of craniopharyngioma. Indeed, advances in the knowledge of the molecular mechanisms at the base of craniopharyngioma oncogenesis will lead to comprehension of the critical checkpoints involved in neoplastic transformation. The final research target will be the definition of new biological agents able to reverse the neoplastic process by acting on these critical checkpoints. This biological approach will lead to a refined therapy combining higher efficacy and safety with lower morbidity. In this paper the authors reveal state-of-the-art comprehension of the molecular biology of craniopharyngioma and the consequent therapeutic implications.",
keywords = "Craniopharyngioma, Molecular biology, Oncogenetic mechanism",
author = "Pettorini, {Benedetta Ludovica} and Paolo Frassanito and Massimo Caldarelli and Tamburrini, {Gianpiero T.} and Luca Massimi and {Di Rocco}, Concezio",
year = "2010",
month = "4",
doi = "10.3171/2010.1.FOCUS09300",
language = "English",
volume = "28",
journal = "Neurosurgical Focus",
issn = "1092-0684",
publisher = "American Association of Neurological Surgeons",
number = "4",

}

TY - JOUR

T1 - Molecular pathogenesis of craniopharyngioma

T2 - Switching from a surgical approach to a biological one

AU - Pettorini, Benedetta Ludovica

AU - Frassanito, Paolo

AU - Caldarelli, Massimo

AU - Tamburrini, Gianpiero T.

AU - Massimi, Luca

AU - Di Rocco, Concezio

PY - 2010/4

Y1 - 2010/4

N2 - Craniopharyngioma has long been considered a benign tumor because of its pathological aspect. This primordial view of craniopharyngioma fit with the primitive treatment attempts based on blind resection of the tumor each time it recurred. The limits of this management strategy were proven early by the high morbidity related to the resection and recurrence risk despite radical lesion removal. Nowadays, craniopharyngioma must be considered a complex molecular disease, and a detailed explanation of the mechanisms underlying its aggressive biological and clinical behavior, despite some benign pathological features, would be the first step toward defining the best management of craniopharyngioma. Indeed, advances in the knowledge of the molecular mechanisms at the base of craniopharyngioma oncogenesis will lead to comprehension of the critical checkpoints involved in neoplastic transformation. The final research target will be the definition of new biological agents able to reverse the neoplastic process by acting on these critical checkpoints. This biological approach will lead to a refined therapy combining higher efficacy and safety with lower morbidity. In this paper the authors reveal state-of-the-art comprehension of the molecular biology of craniopharyngioma and the consequent therapeutic implications.

AB - Craniopharyngioma has long been considered a benign tumor because of its pathological aspect. This primordial view of craniopharyngioma fit with the primitive treatment attempts based on blind resection of the tumor each time it recurred. The limits of this management strategy were proven early by the high morbidity related to the resection and recurrence risk despite radical lesion removal. Nowadays, craniopharyngioma must be considered a complex molecular disease, and a detailed explanation of the mechanisms underlying its aggressive biological and clinical behavior, despite some benign pathological features, would be the first step toward defining the best management of craniopharyngioma. Indeed, advances in the knowledge of the molecular mechanisms at the base of craniopharyngioma oncogenesis will lead to comprehension of the critical checkpoints involved in neoplastic transformation. The final research target will be the definition of new biological agents able to reverse the neoplastic process by acting on these critical checkpoints. This biological approach will lead to a refined therapy combining higher efficacy and safety with lower morbidity. In this paper the authors reveal state-of-the-art comprehension of the molecular biology of craniopharyngioma and the consequent therapeutic implications.

KW - Craniopharyngioma

KW - Molecular biology

KW - Oncogenetic mechanism

UR - http://www.scopus.com/inward/record.url?scp=77953680356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953680356&partnerID=8YFLogxK

U2 - 10.3171/2010.1.FOCUS09300

DO - 10.3171/2010.1.FOCUS09300

M3 - Article

C2 - 20367353

AN - SCOPUS:77953680356

VL - 28

JO - Neurosurgical Focus

JF - Neurosurgical Focus

SN - 1092-0684

IS - 4

ER -